Proteomics International Laboratories Management
Management criteria checks 2/4
Proteomics International Laboratories' CEO is Richard Lipscombe, appointed in Jan 2001, has a tenure of 23.25 years. total yearly compensation is A$442.00K, comprised of 79.2% salary and 20.8% bonuses, including company stock and options. directly owns 12.54% of the company’s shares, worth A$17.98M. The average tenure of the management team and the board of directors is 2.8 years and 2.2 years respectively.
Key information
Richard Lipscombe
Chief executive officer
AU$442.0k
Total compensation
| CEO salary percentage | 79.2% |
| CEO tenure | 23.3yrs |
| CEO ownership | 12.5% |
| Management average tenure | 2.8yrs |
| Board average tenure | 2.2yrs |
Recent management updates
Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable
Nov 16
Here's Why We Think Proteomics International Laboratories Limited's (ASX:PIQ) CEO Compensation Looks Fair for the time being
Nov 17Recent updates
Most Shareholders Will Probably Find That The CEO Compensation For Proteomics International Laboratories Limited (ASX:PIQ) Is Reasonable
Nov 16Calculating The Fair Value Of Proteomics International Laboratories Limited (ASX:PIQ)
Sep 29We're Hopeful That Proteomics International Laboratories (ASX:PIQ) Will Use Its Cash Wisely
May 10Here's Why We Think Proteomics International Laboratories Limited's (ASX:PIQ) CEO Compensation Looks Fair for the time being
Nov 17Is Proteomics International Laboratories (ASX:PIQ) In A Good Position To Invest In Growth?
Aug 09We Think Proteomics International Laboratories (ASX:PIQ) Can Afford To Drive Business Growth
Oct 20We're Not Worried About Proteomics International Laboratories' (ASX:PIQ) Cash Burn
May 31CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | n/a | n/a | -AU$6m |
| Sep 30 2023 | n/a | n/a | -AU$6m |
| Jun 30 2023 | AU$442k | AU$350k | -AU$6m |
| Mar 31 2023 | n/a | n/a | -AU$6m |
| Dec 31 2022 | n/a | n/a | -AU$6m |
| Sep 30 2022 | n/a | n/a | -AU$5m |
| Jun 30 2022 | AU$330k | AU$265k | -AU$5m |
| Mar 31 2022 | n/a | n/a | -AU$5m |
| Dec 31 2021 | n/a | n/a | -AU$4m |
| Sep 30 2021 | n/a | n/a | -AU$4m |
| Jun 30 2021 | AU$298k | AU$250k | -AU$3m |
| Mar 31 2021 | n/a | n/a | -AU$3m |
| Dec 31 2020 | n/a | n/a | -AU$2m |
| Sep 30 2020 | n/a | n/a | -AU$2m |
| Jun 30 2020 | AU$299k | AU$250k | -AU$2m |
| Mar 31 2020 | n/a | n/a | -AU$2m |
| Dec 31 2019 | n/a | n/a | -AU$2m |
| Sep 30 2019 | n/a | n/a | -AU$2m |
| Jun 30 2019 | AU$207k | AU$185k | -AU$2m |
| Mar 31 2019 | n/a | n/a | -AU$2m |
| Dec 31 2018 | n/a | n/a | -AU$2m |
| Sep 30 2018 | n/a | n/a | -AU$2m |
| Jun 30 2018 | AU$156k | AU$170k | -AU$1m |
| Mar 31 2018 | n/a | n/a | -AU$1m |
| Dec 31 2017 | n/a | n/a | -AU$1m |
| Sep 30 2017 | n/a | n/a | -AU$1m |
| Jun 30 2017 | AU$27k | AU$170k | -AU$916k |
Compensation vs Market: Richard's total compensation ($USD288.76K) is about average for companies of similar size in the Australian market ($USD292.80K).
Compensation vs Earnings: Richard's compensation has increased whilst the company is unprofitable.
CEO
Richard Lipscombe
23.3yrs
Tenure
AU$442,000
Compensation
Dr. Richard John Lipscombe, Ph D (London), MA (Oxford), co-founded Proteomics International Laboratories Limited in 2001 and serves as its Managing Director and Director since June 09, 2014. Mr. Lipscombe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 23.3yrs | AU$442.00k | 12.54% A$ 18.0m | |
| Chief Financial Officer | 2.8yrs | AU$305.30k | 0% A$ 0 | |
| Head of Business Development | no data | no data | no data | |
| Head of Research | 2.3yrs | no data | no data | |
| Head of Product Development | 1.8yrs | no data | no data | |
| Chief Commercialisation Officer | 2.8yrs | AU$393.08k | no data | |
| Head of Clinical Studies | no data | no data | no data | |
| Company Secretary | no data | no data | no data |
2.8yrs
Average Tenure
Experienced Management: PIQ's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | AU$442.00k | 12.54% A$ 18.0m | |
| Independent Non-Executive Chairman | 2.4yrs | AU$129.66k | 0.090% A$ 128.8k | |
| Member of Clinical Advisory Board | 2yrs | no data | no data | |
| Independent Non-Executive Director | 7.5yrs | AU$45.00k | 0.75% A$ 1.1m | |
| Independent Non-Executive Director | 2.4yrs | AU$73.12k | no data | |
| Independent Non-Executive Director | 6.4yrs | AU$49.73k | 0.79% A$ 1.1m | |
| Member of Clinical Advisory Board | 2yrs | no data | no data | |
| Member of Clinical Advisory Board | 2yrs | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data | |
| Member of Clinical Advisory Board | 2yrs | no data | no data | |
| Member of Clinical Advisory Board | 2yrs | no data | no data | |
| Member of Clinical Advisory Board | no data | no data | no data |
2.2yrs
Average Tenure
Experienced Board: PIQ's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.